Teva, which is looking to close a $40 billion-plus deal for the generics arm of rival Allergan, struck a pair of divestment deals over the past couple of weeks. But it didn’t stop there.
On Tuesday, Impax Laboratories announced that it, too, was getting in on the action. The Hayward, CA-based company agreed to pay $586 million for a bundle of Teva’s assets.
With the transaction, Impax will grab a range of the Israeli drugmaker’s products, which span various stages of development and regulatory progress. It’s set to pick up 15 already marketed generics, plus three others close to market–one approved generic and two approved dosages of a currently marketed product that haven’t yet launched. The deal also covers one copycat med and another dosage of a currently marketed drug, both awaiting the FDA’s green light. And then there are full commercial rights to Impax’ own pending app for a knockoff of Johnson & Johnson’s ADHD med Concerta, on which it had previously partnered with Teva, and one generic candidate still in development.
It’s a significant get for Impax, which will soon be the proud owner of a portfolio that generated $150 million in 2015 net sales and about $100 million in gross profit last year.
And Teva’s hoping it’s a significant step toward closing a deal that has garnered serious antitrust scrutiny since it was announced last summer. Already this month, the Petah Tivka-based drugmaker has agreed to sell off 5 unapproved generics to Schaumburg, IL’s Sagent Pharmaceuticals, as well as a basket of 8 meds to India’s Dr. Reddy’s ($RDY) for $350 million.
Missing from the party, though, has been Mylan, despite analyst predictions that it would score more products as Teva pruned its lineup. Last November, Mylan lost out on a hostile quest for Ireland’s Perrigo–which some speculate began as an effort to ward off its own hostile suitor, Teva.
But while Mylan may not have snapped up any of Teva’s castoffs, it’s still been active at the M&A table. It recently unveiled a $1 million accord to buy some topical skin treatments from Renaissance Acquisition Holdings, and back in February, it inked a $7.2 billion pact to buy Sweden’s Meda.
By Carly Helfand
Source: Fierce Pharma
The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.
BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.
Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.